Clinical trials: Recurrent Pancreatic Cancer
Adenocarcinoma of the Pancreas, Pancreatic Cancer
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
This phase II trial is studying how well E7389 works as second-line therapy in treating patients with locally advanced, unresectable, or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer
- Trial name
- NCT00383760
- Testing
- eribulin mesylate
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether irofulven is effective in treating pancreatic cancer.
- Trial name
- NCT00033735
- Testing
- fluorouracil, Irofulven
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Eisai Inc.
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer
Pancreatic cancer is an aggressive, largely chemo-resistant disease with a poor prognosis. EGFR and VEGF are both overexpressed in pancreatic cancers and thought to contribute to tumour development and progression.
- Trial name
- TARGET (NCT00260364)
- Testing
- Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle, Capecitabine orally days 1 -21, Erlotinib 100 mg orally days 1-28
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreatic Cancer
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00068432
- Testing
- Celecoxib, Gemcitabine Hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004190
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- 19 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction
Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
RATIONALE: The use of endoscopy to place metal stents in the duodenum is less invasive than surgery for treating cancer-related duodenal obstruction and may have fewer side effects and improve recovery.
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer
- Trial name
- NCT00004910
- Testing
- bowel obstruction management, quality-of-life assessment
- Where
- United States
- Sponsor
- Northwestern University
Pancreatic Cancer
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900016
- Testing
- protein expression analysis, western blotting, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fox Chase Cancer Center
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00735917
- Testing
- saracatinib, pharmacogenomic studies, pharmacological study
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Pancreatic Cancer
UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00045747
- Testing
- 7-hydroxystaurosporine, fluorouracil
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
This phase II trial is studying how well sunitinib works in treating patients with metastatic pancreatic cancer that progressed after first-line therapy with gemcitabine.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00397787
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Thromboembolism
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462852
- Testing
- dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis
- Where
- 8 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Recurrent or Metastatic Cancer, Head and Neck Cancer
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor.
- Conditions
- Recurrent or Metastatic Cancer, Head and Neck Cancer, Pancreas Cancer, Bladder Cancer
- Trial name
- NCT01684098
- Testing
- Tc 99m EC20
- Volunteers
- 40 people
- Sponsor
- Endocyte
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
This phase I trial studies the side effects and the best dose of alisertib when given together with gemcitabine hydrochloride in treating patients with solid tumors or pancreatic cancer that is metastatic or cannot be removed by…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01924260
- Testing
- alisertib, gemcitabine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Edward Kim
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00885066
- Testing
- capecitabine, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Antoine Lacassagne
Pancreatic Cancer
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.
- Trial name
- NCT00044031
- Testing
- G17DT Immunogen
- Volunteers
- 394 people
- Sponsor
- Cancer Advances Inc.
Gastrinoma, Glucagonoma
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00075439
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)